Rimonabant research shows mixed picture

Rimonabant has some benefits at reducing risk factors for heart disease in obese patients, but the overall picture is mixed, international research concludes.A randomised controlled trial comparing rimonabant with placebo in 839...

Sanofi Weight Drug Shows

A weight-loss drug from Sanofi-Aventis SA failed to slow the progression of coronary-artery disease, according to one measure used in a clinical study, but another measure suggested the drug might be able to slow the...

Weight Loss Drug Rimonabant May Not Slow Progression Of Heart Disease

According to a recent study published in JAMA, a clinical trial testing how well the anti-obesity medication rimonabant slowed the development of coronary artery disease in patients with abdominal obesity and pre-existing...

Merck Obesity Drug Helps Shed Pounds, Increases Irritability

Merck & Co.'s experimental obesity pill taranabant helped some people lose three times more weight than diet and exercise and had side effects that include irritability and depressed mood, a study showed.

People taking...

NICE backs rimonabant for obesity

NICE have approved the use of rimonabant for the treatment of both overweight and obese adults, as an adjunct to a controlled diet and regular exercise, for people who are either intolerant or contra-indicated for orlistat and...